Denali Advisors’s Novavax NVAX Stock Holding History

Denali Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-173	Closed	-$830	–	483
2023 Q4	$830	Buy	173 +110	+175%	+$673	﹤0.01%	440
2023 Q3	$456	Buy	+63	New	+$503	﹤0.01%	465

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Denali Advisors's NVAX Position: Q1 2024 in Review

Denali Advisors sold out of Novavax (NVAX) in Q1 2024, closing a stake of 173 shares — an estimated $830 sold.

Denali Advisors first reported a position in NVAX in Q3 2023 and held it in 2 quarters. The position peaked at $830 in Q4 2023. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

Denali Advisors reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
Denali Advisors sold 173 Novavax shares in Q1 2024, an estimated $830.
Denali Advisors first reported a position in Novavax in Q3 2023 and held it in 2 quarters.
Denali Advisors's Novavax position peaked at $830 in Q4 2023.
201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.